__PRESENT__PRESENT
__PRESENT__PRESENT__PRESENT
__PRESENT
__PRESENT
__PRESENT
__PRESENT
__PRESENT__PRESENT__PRESENT__PRESENT__PRESENT
Enter your details to join our mobile app waitlist and receive early access to the Bell Direct App.
Latest stock market podcasts
From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.
In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.
WeMoney 2026
Best for Market Research Insights
Best for Market Research Insights
WeMoney 2025
Best for Market Research Insights
Best for Market Research Insights
WeMoney 2026
Finalist for IPO Access
Finalist for IPO Access
Highest Overall
Client Satisfaction
2013-2023
Client Satisfaction
2013-2023